View ValuationKronox Lab Sciences 将来の成長Future 基準チェック /06現在、 Kronox Lab Sciencesの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Chemicals 収益成長20.5%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesBuy Or Sell Opportunity • Apr 06Now 27% overvaluedOver the last 90 days, the stock has fallen 5.1% to ₹132. The fair value is estimated to be ₹104, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.2% over the last 3 years. Earnings per share has grown by 18%.Valuation Update With 7 Day Price Move • Apr 03Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹118, the stock trades at a trailing P/E ratio of 17x. Average trailing P/E is 20x in the Chemicals industry in India. Total loss to shareholders of 17% over the past year.Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: ₹1.79 (vs ₹1.77 in 3Q 2025)Third quarter 2026 results: EPS: ₹1.79 (up from ₹1.77 in 3Q 2025). Revenue: ₹264.1m (up 10.0% from 3Q 2025). Net income: ₹65.9m (flat on 3Q 2025). Profit margin: 25% (down from 27% in 3Q 2025). The decrease in margin was driven by higher expenses.お知らせ • Feb 09Kronox Lab Sciences Limited to Report Q3, 2026 Results on Feb 14, 2026Kronox Lab Sciences Limited announced that they will report Q3, 2026 results at 12:08 PM, Indian Standard Time on Feb 14, 2026Reported Earnings • Nov 12Second quarter 2026 earnings released: EPS: ₹1.82 (vs ₹1.76 in 2Q 2025)Second quarter 2026 results: EPS: ₹1.82 (up from ₹1.76 in 2Q 2025). Revenue: ₹265.8m (up 6.9% from 2Q 2025). Net income: ₹66.8m (up 3.1% from 2Q 2025). Profit margin: 25% (in line with 2Q 2025).お知らせ • Nov 04Kronox Lab Sciences Limited to Report Q2, 2026 Results on Nov 11, 2025Kronox Lab Sciences Limited announced that they will report Q2, 2026 results on Nov 11, 2025Board Change • Sep 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. Non Executive-Independent Women Director Krutika Negandhi was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Aug 06Kronox Lab Sciences Limited to Report Q1, 2026 Results on Aug 11, 2025Kronox Lab Sciences Limited announced that they will report Q1, 2026 results on Aug 11, 2025Upcoming Dividend • Aug 01Upcoming dividend of ₹0.50 per shareEligible shareholders must have bought the stock before 08 August 2025. Payment date: 17 September 2025. Payout ratio is a comfortable 7.3% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.2%). Lower than average of industry peers (0.7%).Reported Earnings • Jul 29Full year 2025 earnings released: EPS: ₹6.86 (vs ₹5.75 in FY 2024)Full year 2025 results: EPS: ₹6.86 (up from ₹5.75 in FY 2024). Revenue: ₹1.00b (up 12% from FY 2024). Net income: ₹254.7m (up 19% from FY 2024). Profit margin: 25% (up from 24% in FY 2024). The increase in margin was driven by higher revenue.お知らせ • Jul 28Kronox Lab Sciences Limited, Annual General Meeting, Aug 18, 2025Kronox Lab Sciences Limited, Annual General Meeting, Aug 18, 2025, at 11:00 Indian Standard Time.お知らせ • Jul 26Kronox Lab Sciences Limited announces Annual dividend, payable on September 17, 2025Kronox Lab Sciences Limited announced Annual dividend of INR 0.5000 per share payable on September 17, 2025, ex-date on August 08, 2025 and record date on August 08, 2025.Buy Or Sell Opportunity • Jul 07Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 45% to ₹202. The fair value is estimated to be ₹168, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.3% over the last 3 years. Earnings per share has grown by 22%.Valuation Update With 7 Day Price Move • Jun 26Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹188, the stock trades at a trailing P/E ratio of 27.3x. Average trailing P/E is 29x in the Chemicals industry in India. Total returns to shareholders of 25% over the past year.Valuation Update With 7 Day Price Move • May 30Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹172, the stock trades at a trailing P/E ratio of 25.1x. Average trailing P/E is 27x in the Chemicals industry in India.Reported Earnings • May 23Full year 2025 earnings released: EPS: ₹6.91 (vs ₹5.75 in FY 2024)Full year 2025 results: EPS: ₹6.91 (up from ₹5.75 in FY 2024). Revenue: ₹1.03b (up 14% from FY 2024). Net income: ₹254.7m (up 19% from FY 2024). Profit margin: 25% (up from 24% in FY 2024). The increase in margin was driven by higher revenue.お知らせ • May 19Kronox Lab Sciences Limited to Report Q4, 2025 Results on May 22, 2025Kronox Lab Sciences Limited announced that they will report Q4, 2025 results on May 22, 2025Reported Earnings • Feb 02Third quarter 2025 earnings released: EPS: ₹1.77 (vs ₹1.29 in 3Q 2024)Third quarter 2025 results: EPS: ₹1.77 (up from ₹1.29 in 3Q 2024). Revenue: ₹248.3m (up 20% from 3Q 2024). Net income: ₹65.3m (up 38% from 3Q 2024). Profit margin: 26% (up from 23% in 3Q 2024). The increase in margin was driven by higher revenue.お知らせ • Jan 23Kronox Lab Sciences Limited to Report Q3, 2025 Results on Jan 31, 2025Kronox Lab Sciences Limited announced that they will report Q3, 2025 results on Jan 31, 2025Valuation Update With 7 Day Price Move • Nov 27Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹191, the stock trades at a trailing P/E ratio of 30.5x. Average trailing P/E is 32x in the Chemicals industry in India.New Risk • Nov 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.8% average weekly change). Market cap is less than US$100m (₹6.87b market cap, or US$81.4m).お知らせ • Oct 31Kronox Lab Sciences Limited to Report Q2, 2025 Results on Nov 12, 2024Kronox Lab Sciences Limited announced that they will report Q2, 2025 results on Nov 12, 2024Valuation Update With 7 Day Price Move • Oct 14Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹175, the stock trades at a trailing P/E ratio of 30.8x. Average trailing P/E is 35x in the Chemicals industry in India.Valuation Update With 7 Day Price Move • Aug 29Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹182, the stock trades at a trailing P/E ratio of 31.9x. Average trailing P/E is 36x in the Chemicals industry in India.お知らせ • Aug 09Kronox Lab Sciences Limited, Annual General Meeting, Aug 30, 2024Kronox Lab Sciences Limited, Annual General Meeting, Aug 30, 2024, at 11:00 Indian Standard Time. Location: Block no. 353, Village: Ekalbara, Taluka: Padra, District: Vadodara 391440 IndiaReported Earnings • Aug 07First quarter 2025 earnings released: EPS: ₹1.67 (vs ₹0.64 in 1Q 2024)First quarter 2025 results: EPS: ₹1.67 (up from ₹0.64 in 1Q 2024). Revenue: ₹256.2m (up 19% from 1Q 2024). Net income: ₹61.5m (up 152% from 1Q 2024). Profit margin: 24% (up from 11% in 1Q 2024). The increase in margin was driven by higher revenue.お知らせ • Jul 29Kronox Lab Sciences Limited to Report Q1, 2025 Results on Aug 06, 2024Kronox Lab Sciences Limited announced that they will report Q1, 2025 results on Aug 06, 2024お知らせ • Jun 22Kronox Lab Sciences Limited to Report Q4, 2024 Results on Jun 28, 2024Kronox Lab Sciences Limited announced that they will report Q4, 2024 results on Jun 28, 2024Board Change • Jun 11Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Satish Kumar was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Kronox Lab Sciences は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測BSE:544187 - アナリストの将来予測と過去の財務データ ( )INR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20251,012260N/AN/AN/A9/30/20251,000259230269N/A6/30/2025993256N/AN/AN/A3/31/20251,002255276307N/A12/31/2024962250N/AN/AN/A9/30/2024929232N/AN/AN/A6/30/2024891211N/AN/AN/A3/31/202489921451174N/A12/31/202389218062175N/A3/31/2023956164113197N/A3/31/20228241365290N/A3/31/20216269797113N/A3/31/2020508853248N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 544187の予測収益成長が 貯蓄率 ( 6.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 544187の収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 544187の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 544187の収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 544187の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 544187の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/09 03:42終値2026/05/08 00:00収益2025/12/31年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Kronox Lab Sciences Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Buy Or Sell Opportunity • Apr 06Now 27% overvaluedOver the last 90 days, the stock has fallen 5.1% to ₹132. The fair value is estimated to be ₹104, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.2% over the last 3 years. Earnings per share has grown by 18%.
Valuation Update With 7 Day Price Move • Apr 03Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹118, the stock trades at a trailing P/E ratio of 17x. Average trailing P/E is 20x in the Chemicals industry in India. Total loss to shareholders of 17% over the past year.
Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: ₹1.79 (vs ₹1.77 in 3Q 2025)Third quarter 2026 results: EPS: ₹1.79 (up from ₹1.77 in 3Q 2025). Revenue: ₹264.1m (up 10.0% from 3Q 2025). Net income: ₹65.9m (flat on 3Q 2025). Profit margin: 25% (down from 27% in 3Q 2025). The decrease in margin was driven by higher expenses.
お知らせ • Feb 09Kronox Lab Sciences Limited to Report Q3, 2026 Results on Feb 14, 2026Kronox Lab Sciences Limited announced that they will report Q3, 2026 results at 12:08 PM, Indian Standard Time on Feb 14, 2026
Reported Earnings • Nov 12Second quarter 2026 earnings released: EPS: ₹1.82 (vs ₹1.76 in 2Q 2025)Second quarter 2026 results: EPS: ₹1.82 (up from ₹1.76 in 2Q 2025). Revenue: ₹265.8m (up 6.9% from 2Q 2025). Net income: ₹66.8m (up 3.1% from 2Q 2025). Profit margin: 25% (in line with 2Q 2025).
お知らせ • Nov 04Kronox Lab Sciences Limited to Report Q2, 2026 Results on Nov 11, 2025Kronox Lab Sciences Limited announced that they will report Q2, 2026 results on Nov 11, 2025
Board Change • Sep 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. Non Executive-Independent Women Director Krutika Negandhi was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Aug 06Kronox Lab Sciences Limited to Report Q1, 2026 Results on Aug 11, 2025Kronox Lab Sciences Limited announced that they will report Q1, 2026 results on Aug 11, 2025
Upcoming Dividend • Aug 01Upcoming dividend of ₹0.50 per shareEligible shareholders must have bought the stock before 08 August 2025. Payment date: 17 September 2025. Payout ratio is a comfortable 7.3% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.2%). Lower than average of industry peers (0.7%).
Reported Earnings • Jul 29Full year 2025 earnings released: EPS: ₹6.86 (vs ₹5.75 in FY 2024)Full year 2025 results: EPS: ₹6.86 (up from ₹5.75 in FY 2024). Revenue: ₹1.00b (up 12% from FY 2024). Net income: ₹254.7m (up 19% from FY 2024). Profit margin: 25% (up from 24% in FY 2024). The increase in margin was driven by higher revenue.
お知らせ • Jul 28Kronox Lab Sciences Limited, Annual General Meeting, Aug 18, 2025Kronox Lab Sciences Limited, Annual General Meeting, Aug 18, 2025, at 11:00 Indian Standard Time.
お知らせ • Jul 26Kronox Lab Sciences Limited announces Annual dividend, payable on September 17, 2025Kronox Lab Sciences Limited announced Annual dividend of INR 0.5000 per share payable on September 17, 2025, ex-date on August 08, 2025 and record date on August 08, 2025.
Buy Or Sell Opportunity • Jul 07Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 45% to ₹202. The fair value is estimated to be ₹168, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.3% over the last 3 years. Earnings per share has grown by 22%.
Valuation Update With 7 Day Price Move • Jun 26Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹188, the stock trades at a trailing P/E ratio of 27.3x. Average trailing P/E is 29x in the Chemicals industry in India. Total returns to shareholders of 25% over the past year.
Valuation Update With 7 Day Price Move • May 30Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹172, the stock trades at a trailing P/E ratio of 25.1x. Average trailing P/E is 27x in the Chemicals industry in India.
Reported Earnings • May 23Full year 2025 earnings released: EPS: ₹6.91 (vs ₹5.75 in FY 2024)Full year 2025 results: EPS: ₹6.91 (up from ₹5.75 in FY 2024). Revenue: ₹1.03b (up 14% from FY 2024). Net income: ₹254.7m (up 19% from FY 2024). Profit margin: 25% (up from 24% in FY 2024). The increase in margin was driven by higher revenue.
お知らせ • May 19Kronox Lab Sciences Limited to Report Q4, 2025 Results on May 22, 2025Kronox Lab Sciences Limited announced that they will report Q4, 2025 results on May 22, 2025
Reported Earnings • Feb 02Third quarter 2025 earnings released: EPS: ₹1.77 (vs ₹1.29 in 3Q 2024)Third quarter 2025 results: EPS: ₹1.77 (up from ₹1.29 in 3Q 2024). Revenue: ₹248.3m (up 20% from 3Q 2024). Net income: ₹65.3m (up 38% from 3Q 2024). Profit margin: 26% (up from 23% in 3Q 2024). The increase in margin was driven by higher revenue.
お知らせ • Jan 23Kronox Lab Sciences Limited to Report Q3, 2025 Results on Jan 31, 2025Kronox Lab Sciences Limited announced that they will report Q3, 2025 results on Jan 31, 2025
Valuation Update With 7 Day Price Move • Nov 27Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹191, the stock trades at a trailing P/E ratio of 30.5x. Average trailing P/E is 32x in the Chemicals industry in India.
New Risk • Nov 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.8% average weekly change). Market cap is less than US$100m (₹6.87b market cap, or US$81.4m).
お知らせ • Oct 31Kronox Lab Sciences Limited to Report Q2, 2025 Results on Nov 12, 2024Kronox Lab Sciences Limited announced that they will report Q2, 2025 results on Nov 12, 2024
Valuation Update With 7 Day Price Move • Oct 14Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹175, the stock trades at a trailing P/E ratio of 30.8x. Average trailing P/E is 35x in the Chemicals industry in India.
Valuation Update With 7 Day Price Move • Aug 29Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹182, the stock trades at a trailing P/E ratio of 31.9x. Average trailing P/E is 36x in the Chemicals industry in India.
お知らせ • Aug 09Kronox Lab Sciences Limited, Annual General Meeting, Aug 30, 2024Kronox Lab Sciences Limited, Annual General Meeting, Aug 30, 2024, at 11:00 Indian Standard Time. Location: Block no. 353, Village: Ekalbara, Taluka: Padra, District: Vadodara 391440 India
Reported Earnings • Aug 07First quarter 2025 earnings released: EPS: ₹1.67 (vs ₹0.64 in 1Q 2024)First quarter 2025 results: EPS: ₹1.67 (up from ₹0.64 in 1Q 2024). Revenue: ₹256.2m (up 19% from 1Q 2024). Net income: ₹61.5m (up 152% from 1Q 2024). Profit margin: 24% (up from 11% in 1Q 2024). The increase in margin was driven by higher revenue.
お知らせ • Jul 29Kronox Lab Sciences Limited to Report Q1, 2025 Results on Aug 06, 2024Kronox Lab Sciences Limited announced that they will report Q1, 2025 results on Aug 06, 2024
お知らせ • Jun 22Kronox Lab Sciences Limited to Report Q4, 2024 Results on Jun 28, 2024Kronox Lab Sciences Limited announced that they will report Q4, 2024 results on Jun 28, 2024
Board Change • Jun 11Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Satish Kumar was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.